SoRI-20041

From Wikipedia, the free encyclopedia
Jump to: navigation, search
SoRI-20041
SoRI-20041.png
Systematic (IUPAC) name
N-(3,3-diphenylpropyl)-2-phenyl-4-quinazolinamine
Identifiers
PubChem CID 44310972
Chemical data
Formula C29H25N3
Molar mass 415.528 g/mol

SoRI-20041 is an "antagonist-like" allosteric modulator of amphetamine-induced dopamine release[1] (in contrast to the related research chemicals SoRI-9804 and SoRI-20040, which are "agonist-like").[1] SoRI-20041 is believed to be the first example of a drug that separately modulates uptake versus release in the dopamine transporter (possibly showing how inward and outward transport represent distinct operational modes of DAT); it produces the same effects as SoRI-20040 and SoRI-9804 in uptake assays and binding assays, inhibiting the re-uptake of dopamine, but does not modulate d-amphetamine-induced DA release by inhibiting that as well, like 'agonists' of the series do.[1]

This suggests the possibility of simultaneous action and increase of indirect-agonism through the dual action of DRA and DRI efficacy existing together. This increases the inhibition of re-uptake at synaptic dopamine concentrations without interfering in the flow of release of dopamine from amphetaminergic phosphorylation at the affected transporter. This overcomes the obstacle of a compromised binding site that would be rendered unusable through the action of amphetamine. Conventional dopamine re-uptake inhibitors (such as cocaine or methylphenidate) would otherwise ineffectively target such a site on each specific transporter so affected by amphetamine, making this an example of a DRI that does not have a mutually exclusive functionality against DRA action at individual instances of DAT.

References[edit]

  1. ^ a b c Rothman, R. B.; Dersch, C. M.; Ananthan, S.; Partilla, J. S. (2009). "Studies of the Biogenic Amine Transporters. 13. Identification of "Agonist" and "Antagonist" Allosteric Modulators of Amphetamine-Induced Dopamine Release" (pdf). The Journal of Pharmacology and Experimental Therapeutics. 329 (2): 718–728. doi:10.1124/jpet.108.149088. PMC 2672863free to read. PMID 19244097. 
SoRI-20040